OverviewChartNewsTraderScreen

L&S Knock-Out AYJ 11.06.2024/  DE000LX3ZFK6  /

EUWAX
2024-05-23  11:30:31 AM Chg.+0.02 Bid11:55:50 AM Ask11:55:50 AM Underlying Strike price Expiration date Option type
1.96EUR +1.03% 1.92
Bid Size: 2,000		 1.97
Ask Size: 2,000		 VALNEVA SE EO... 2.25 EUR 2024-06-11 Call
GlobeNewswire 05-21 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GlobeNewswire 05-13 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire 05-07 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 03-26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GlobeNewswire 03-25 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire 03-21 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire 03-20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 03-18 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire 03-04 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire 02-29 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire 02-15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 02-05 Valneva Announces Sale of Priority Review Voucher for $103 Million
GlobeNewswire 01-10 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
GlobeNewswire 01-04 Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Foru...
GlobeNewswire 2023-12-29 Valneva Provides Updated 2023 Financial Guidance
GlobeNewswire 2023-12-04 Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...
GlobeNewswire 2023-12-04 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine ...
GlobeNewswire 2023-11-27 EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assess...
GlobeNewswire 2023-11-15 Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including ...
GlobeNewswire 2023-11-13 Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chik...
GlobeNewswire 2023-11-10 Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
GlobeNewswire 2023-11-09 Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire 2023-11-07 Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
GlobeNewswire 2023-11-07 Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
GlobeNewswire 2023-10-25 Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Asse...